2023-08-11T08:19:08-05:00 2022-09-30 390859910 BAKER TILLY US LLP 225 S 6TH ST 2300 MINNEAPOLIS MN 55402 990 2021-10-01 411704734 BE THE MATCH FOUNDATION BETH 7634068700 500 N 5TH ST MINNEAPOLIS MN 554011206 KRISTA DUSIL CHIEF FINANCIAL OFFICER 7634068700 2023-08-10 1 KRISTA DUSIL XXX-XX-XXXX LAWRENCE H MOHR CPA P00447603 6128764500 2023-08-10 0 AAL1 IAL1 2021 2023-04-26 12:10:37Z JOY KING 500 N 5TH ST MINNEAPOLIS MN 554011206 13991112 0 X WWW.BETHEMATCH.ORG X 1991 MN RAISES FUNDS TO SUPPORT THE NMDP MISSION: WE SAVE LIVES THROUGH CELLULAR THERAPY. 19 18 43 2934 0 0 20737956 13066515 0 0 491516 283656 -62198 -548424 21167274 12801747 8823427 10956064 0 0 4124427 4686099 699201 418679 1708894 -113509 1716828 13533546 17777670 7633728 -4975923 21284478 15501279 999743 2624098 20284735 12877181 X RAISES FUNDS TO SUPPORT THE NMDP MISSION: WE SAVE LIVES THROUGH CELLULAR THERAPY 0 0 6140620 6140620 PATIENT ASSISTANCE:BE THE MATCH FOUNDATION (BTMF) PROVIDES FINANCIAL ASSISTANCE TO PATIENTS THROUGHOUT EACH STAGE OF THE TRANSPLANT PROCESS. FUNDED FULLY BY PHILANTROHY, IN FY22 MORE THAN $4.6 MILLION WAS PROVIDED TO OVER 1,900 PATIENTS FROM 135 TRANSPLANT CENTERS. IN FY22 THE PROPORTION OF GRANT RECIPIENTS WHO IDENTIFY AS NON-HISPANIC WHITE RANGED FROM 58%-83% DEPENDING ON THE GRANT TYPE. THE CHELL TRAVEL GRANT, WHICH HELPS PEOPLE WITH TRAVEL COSTS ASSOCIATED WITH PARTICIPATING IN A CLINICAL TRIAL, WAS DISTRIBUTED TO THE MOST DIVERSE POPULATION, WITH 58% OF GRANT RECIPIENTS IDENTIFYING AS NON-HISPANIC WHITE. THE SEARCH ASSISTANCE FUND GRANT WAS DISTRIBUTED TO THE LEAST DIVERSE POPULATION, WITH 83% OF RECIPIENTS IDENTIFYING AS NON-HISPANIC WHITE. THE SEARCH ASSISTANCE FUND GRANT PROGRAMS (SAF) SUPPORT PATIENTS PRE-TRANSPLANT WHO HAVE INSURANCE AND FINANCIAL BARRIERS THAT DELAY OR PREVENT THEM FROM FINDING A DONOR OR CORD BLOOD UNIT. THIS GRANT HELPS PATIENTS START THE SEARCH FOR AN UNRELATED DONOR OR CORD BLOOD UNIT BY GIVING TRANSPLANT CENTERS A GUARANTEE OF PAYMENT FOR SPECIFIC SEARCH AND/OR PROCUREMENT COSTS SHOULD THEY NOT BE COVERED BY INSURANCE. THERE WERE 136 PATIENTS APPROVED FOR SAF THIS FISCAL YEAR. BTMF ALSO PROVIDES FUNDING TO HELP WITH THE MANY UNCOVERED OUT-OF-POCKET EXPENSES FOR PATIENTS BEFORE AND AFTER A TRANSPLANT. THE TRANSPLANT SUPPORT ASSISTANCE (TSA) GRANT PROVIDES DIRECT FINANCIAL ASSISTANCE TO QUALIFIED FAMILIES BOTH PRE- AND POST-TRANSPLANT. TSA HELPS WITH EXPENSES SUCH AS TRANSPORTATION, TEMPORARY RELOCATION, CO-PAYS, AND INSURANCE PREMIUMS. THIS YEAR 1,928 TSA AWARDS WERE GRANTED WITH THE AVERAGE AWARD BEING $1,746 TO PATIENTS PRE- AND POST-TRANPLANT.THE JOHN AND CARYN CAMIOLO SURVIVORSHIP GRANT (CAM) PROVIDES DIRECT FINANCIAL ASSISTANCE TO QUALIFIED PATIENTS, WHO ARE AT LEAST THREE MONTHS POST-TRANSPLANT AND WHO ARE ACTIVELY RECEIVING TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE. CAM HELPS WITH UNCOVERED COSTS OF TREATMENT AND PRESCRIPTIONS. IN FY22, 109 PATIENTS WERE HELPED THROUGH THE CAM GRANT WITH EACH PATIENT AWARDED $750.THE CHELL TRAVEL GRANT PROVIDES DIRECT FINANCIAL ASSISTANCE TO QUALIFIED PATIENTS WHO NEEDED ASSISTANCE WITH TRAVEL COSTS TO PARTICIPATE IN CLINICAL TRIALS THAT TREAT BLOOD CANCERS OR BLOOD DISORDERS. THIS YEAR 99 CHELL TRAVEL GRANTS WERE AWARDED WITH THE AVERAGE AWARD AMOUNT BEING $3,536.TWO CRISIS GRANTS HELP PATIENTS EXPERIENCING A SIGNIFICANT CRISIS EVENT IMPACTING ACCESS TO TRANSPLANT OR POST-TRANSPLANT CARE. THE IRA AND DIANA RIKLIS CRISIS GRANT PROVIDES UP TO $10,000 IN DIRECT FINANCIAL ASSISTANCE TO QUALIFIED PATIENTS POST-TRANSPLANT AND THE MAKE ME STRONGER CRISIS GRANT PROVIDES UP TO $15,000 PRE-TRANSPLANT. THIS FISCAL YEAR, 15 PATIENTS WERE HELPED THROUGH THESE CRISIS GRANTS WITH THE AVERAGE AWARD AMOUNT BEING $8,600. A COMMITTEE REVIEWS EACH CRISIS GRANT APPLICATION WITH RACE/ETHNICITY INFORMATION REDACTED TO INCREASE THE EQUITABLE DISTRIBUTION OF THIS GRANT. IN FY22, 73% OF GRANT RECIPIENTS IDENTIFIED AS NON-HISPANIC WHITE. 3566119 3566119 RESEARCH:RESEARCH INNOVATIONS ARE CRITICAL TO EXPANDING TREATMENT TO MORE PATIENTS AND IMPROVING OUTCOMES. EACH YEAR, BTMF IS PROUD TO INVEST IN RESEARCH THROUGH:THE AMY STRELZER MANASEVIT RESEARCH PROGRAM (AMY PROGRAM): OUR FLAGSHIP RESEARCH FELLOWSHIP, THE AMY PROGRAM FUNDS EARLY CAREER INVESTIGATORS FOCUSED ON ADVANCES IN THE PREVENTION AND TREATMENT OF POST-CELL THERAPY COMPLICATIONS (E.G., GRAFT-VERSUS-HOST-DISEASE AND INFECTION). IN 2022, WE FUNDED THE WORK OF 15 AMY SCHOLARS. AMY SCHOLARS HAVE GONE ON TO BECOME LEADERS IN THE FIELD, PURSUING SCIENTIFIC ADVANCES THAT HELP BE THE MATCH PATIENTS LIVE LONGER, HEALTHIER LIVES. SINCE 1998, BTMF HAS INVESTED NEARLY $12 MILLION TO HELP LAUNCH THE CAREERS OF 47 YOUNG PHYSICIAN-SCIENTISTS. AFTER RECEIVING THEIR AMY SCHOLAR AWARDS, THIS GROUP HAS GONE ON TO WIN MORE THAN $110 MILLION IN SUBSEQUENT FUNDING TO PURSUE THE DISCOVERIES THAT WILL HELP PATIENTS LIVE LONGER, HEALTHIER LIVES AFTER CELL THERAPY. TODAY, THE AMY STRELZER MANASEVIT RESEARCH PROGRAM FOR THE STUDY OF POST-CELL THERAPY COMPLICATIONS IS ONE OF THE LARGEST AND MOST COVETED FELLOWSHIPS IN THE FIELD OF TRANSPLANTATION.ACCESS/DONOR FOR ALL: THIS TRANSFORMATIONAL MULTI-CENTER STUDY IS TESTING A NEW TRANSPLANT PROTOCOL AIMED AT MAKING MISMATCHED DONOR TRANSPLANTS SAFER AND MORE EFFECTIVE, WITH THE GOAL OF EXPANDING ACCESS TO TRANSPLANT TO THOUSANDS OF PATIENTS WHO LACK A FULLY MATCHED DONOR. COVID-19 VACCINATION STUDY: CIBMTR LAUNCHED A MULTI-CENTER STUDY IN 2020 TO TRACK COVID-19 VACCINATION RESPONSE IN PATIENTS WHO HAVE RECEIVED A TRANSPLANT OR CAR-T CELL THERAPY, WITH THE GOAL OF UNDERSTANDING SAFETY, EFFICACY, AND DURABILITY OF RESPONSES TO VACCINATION. ANTHONY NOLAN TRUST: PROVIDE SUPPORT TO THE ANTHONY NOLAN RESEARCH INSTITUTE TO CONTINUE DEVELOPMENT AND MAINTENANCE OF AN HLA CLASS I AND II SEQUENCE DATABASE AND PROVISION OF HLA CLASS I AND II SEQUENCE INFORMATION. BE THE MATCH'S CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH (CIBMTR)- A PARTNERSHIP WITH THE MEDICAL COLLEGE OF WISCONSIN- IS THE LEADING HUB FOR TRANSPLANT AND CELL THERAPY RESEARCH. BTMF HELPS TO FUND INNOVATIVE RESEARCH STUDIES LED AND MANAGED BY THE CIBMTR 100000 100000 RECRUITMENT:THE BE THE MATCH REGISTRY PROVIDES THE MOST DIVERSE LISTING OF POTENTIAL DONORS AND CORD BLOOD UNITS IN THE WORLD, WITH ACCESS TO MORE THAN 41 MILLION POTENTIAL DONORS AND 811,000 CORD BLOOD UNITS WORLDWIDE. IN FY2022, OVER 308,000 NEW POTENTIAL DONORS WERE ADDED TO THE BE THE MATCH REGISTRY. ALTHOUGH THERE ARE MILLIONS ON THE REGISTRY, PATIENTS SOMETIMES STILL CANNOT FIND A MATCH. THIS IS DUE IN PART TO THE PATIENT'S ETHNIC BACKGROUND. ON AVERAGE, A PATIENT'S LIKELIHOOD OF FINDING A MATCH ON THE BE THE MATCH REGISTRY RANGES FROM 29% TO 79% DEPENDING ON THE ETHNIC BACKGROUND. SOME ETHNIC GROUPS HAVE MORE COMPLEX TISSUE TYPES THAN OTHERS, SO A PERSON'S BEST CHANCE OF FINDING A DONOR IS WITH SOMEONE OF THE SAME ETHNIC BACKGROUND. THE IMPORTANCE OF INCREASING DIVERSITY ON THE REGISTRY IS AN ORGANIZATION GOAL AND PRIORITY AT BE THE MATCH. 5524271 1149325 BTMF PARTNERS WITH BE THE MATCH ON VARIOUS INITIATIVES TIED TO THE SHARED MISSION. THESE PROGRAMS INCLUDE:BE THE MATCH PROVIDES COMPREHENSIVE EDUCATION AND SUPPORT SERVICES TO PATIENTS AND THEIR FAMILIES THROUGH ONE-ON-ONE NAVIGATION SUPPORT, VIDEO, PRINTED, AND DIGITAL EDUCATION RESOURCES, COUNSELING, PEER-TO-PEER CONNECT PROGRAM, SURVIVORSHIP PROGRAM, AND THE JASON CARTER CLINICAL TRIALS SEARCH AND SUPPORT PROGRAM, WHICH HELPS PATIENTS WITH LIFE-THREATENING BLOOD DISORDERS FIND CLINICAL TRIALS. BMTF RAISES FUNDS TO SUPPORT THESE CRITICAL SERVICES. A MEDIA CAMPAIGN FOCUSED ON AWARENESS OF OUR MISSION TO NEW AUDIENCES WAS LAUNCHED IN FY22. THIS CAMPAIGN FEATURES CELTICS PLAYER AND DEFENSIVE PLAYER OF THE YEAR MARCUS SMART, WHOSE PERSONAL CONNECTION WITH BLOOD DISEASE INSPIRED A SOCIAL MEDIA DRIVE TO SUPPORT A SEARCHING PATIENT. BTMF ALLOCATES COMPENSATION AND BENEFITS AND OCCUPANCY COSTS TO PROGRAM BASED ON EMPLOYEE RESPONSIBILITIES. 5524271 1149325 15331010 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 1 0 0 1 0 1 1 1 1 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 1 228 0 1 43 1 0 1 MX 0 0 0 1 1 0 0 0 0 0 0 X 19 18 1 0 0 0 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AR CA FL GA HI IL KS KY MA MD MI MN MS NH NJ NM NY NC OR PA RI SC TN UT VA WV WI X X KRISTA DUSIL 7634064275 500 N 5TH ST MINNEAPOLIS MN 554011206 AMY RONNEBERG CHIEF EXECUTIVE OFFICER 2.00 48.00 X X 0 1180217 25519 ANNE MCGEORGE CHAIR 1.00 0.00 X 0 0 0 MICHAEL STEWART VICE CHAIR 1.00 0.00 X 0 0 0 DIANA CARTER TREASURER 1.00 0.00 X 0 0 0 ROGER PASCHKE SECRETARY 1.00 0.00 X 0 0 0 ANDREW BLOCK DIRECTOR 1.00 0.00 X 0 0 0 ANNIE BALLANTINE DIRECTOR 1.00 0.00 X 0 0 0 BRUCE MANASEVIT DIRECTOR 1.00 0.00 X 0 0 0 DAVID PEARCE DIRECTOR 1.00 0.00 X 0 0 0 DERYN POMEROY DIRECTOR 1.00 0.00 X 0 0 0 GUSTAVO ALCOCER DIRECTOR 1.00 0.00 X 0 0 0 JASON AHLGREN DIRECTOR 1.00 0.00 X 0 0 0 JOSEPH LOUGHRAN DIRECTOR 1.00 0.00 X 0 0 0 MELISSA KONG DIRECTOR 1.00 0.00 X 0 0 0 MICHAEL ROSE DIRECTOR 1.00 0.00 X 0 0 0 NICOLE MOORE DIRECTOR 1.00 0.00 X 0 0 0 RAMESH SUBRHMANIAN DIRECTOR 1.00 0.00 X 0 0 0 RAYNE ROUCE DIRECTOR 1.00 0.00 X 0 0 0 RENE SIGMAN DIRECTOR 1.00 0.00 X 0 0 0 THOMAS TEACH DIRECTOR 1.00 0.00 X 0 0 0 KRISTA DUSIL CHIEF FINANCIAL OFFICER 1.00 49.00 X 0 312246 18105 JOY KING EXEC. DIR. BTMF/SVP PHILAN. 20.00 30.00 X 172807 259210 48354 TODD A PETERSON VICE PRESIDENT 50.00 0.00 X 207645 0 40900 ANGIE FITZGERALD SENIOR DIR., CORPORATE PARTNERSHIPS 50.00 0.00 X 162123 0 34504 DANIEL LEE DIRECTOR, MAJOR AND PLANNED GIFTS 50.00 0.00 X 161555 0 25294 JACQUELINE CHANDONNET DIRECTOR, DEVELOPMENT 50.00 0.00 X 160435 0 20479 KRISTIN SCOTT MANAGER, MAJOR GIFTS 50.00 0.00 X 149534 0 13860 GINA GRAVES FORMER OFFICER 0.00 0.00 X 0 306000 35689 JEFFREY CHELL FORMER OFFICER 0.00 0.00 X 0 101795 0 1014099 2159468 262704 13 1 1 0 ALLEGIANCE FUNDRAISING GROUP PO 9132 FARGO ND 581069132 FUNDRAISING SUPPORT 398037 STREAMWORKS 3640 PHEASANT RIDGE DRIVE NORTHEAST BLAINE MN 55449 CREATIVE, PRINT & MAIL SERVICES 269976 BLACKBAUD PO BOX 930256 ATLANTA GA 31193 SOFTWARE SUPPORT 157967 GOODUNITED INKIND 1306 SHIRE ROAD MT PLEASANT SC 29464 FUNDRAISING SUPPORT 107627 4 2171032 1584800 9310683 272900 13066515 293611 293611 494468 504423 -9955 -9955 -9955 109988 2171032 678967 -568979 -568979 26600 5975 20625 20625 FOREIGN CURRENCY GAIN/ 900099 -70 -70 -70 12801747 0 0 -264768 6050393 6050393 4899926 4899926 5745 5745 209897 143645 23726 42526 3453901 2363702 390422 699777 260811 178488 29482 52841 491070 336067 55510 99493 270420 185064 30568 54788 25000 25000 418679 418679 11652 11652 1047166 806318 20943 219905 88339 31802 5300 51237 1390 1070 28 292 164012 112242 18540 33230 272887 199207 65493 8187 14353 14353 RECOGNITION 48170 17341 2890 27939 REGISTRATIONS/MEMBERSHI 43859 43859 17777670 15331010 737766 1708894 0 0 5371228 1771547 3318740 3374111 286639 190388 294221 75054 0 0 0 0 12013650 10090179 21284478 15501279 999743 2624098 999743 2624098 X 11125976 5784204 9158759 7092977 20284735 12877181 21284478 15501279 -4975923 -2431631 0 X X 0 1 X 1 0 X 11051487 10751245 18034650 20737956 13066515 73641853 11051487 10751245 18034650 20737956 13066515 73641853 23225154 50416699 229695 247043 238703 260691 293611 1269743 3 -70 -67 74911529 -18779 0.67300 0.64030 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: FOREIGN CURRENCY GAIN - 2017 AMOUNT: $ 0. 2018 AMOUNT: $ 0. 2019 AMOUNT: $ 0. 2020 AMOUNT: $ 3. 2021 AMOUNT: $ -70. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 5550447 465 -832236 172000 4552 4542124 5098748 60000 554109 160000 2410 5550447 4612433 200500 285815 5098748 1407960 2963973 240500 4612433 1407960 1407960 0.62690 0.37310 0 0 0 X 12013406 -2431631 970000 684942 -776689 12790095 11652 11652 12801747 19420960 970000 684942 1654942 17766018 11652 11652 17777670 PART V, LINE 4: THE INTENDED USES OF THE ENDOWMENT FUNDS ARE TO SUPPORT RESEARCH AND PATIENT ASSISTANCE GRANTS. PART X, LINE 2: ORGANIZATION'S LIABILITY FOR UNCERTAIN TAX POSITIONS UNDER ASC 740 THE INTERNAL REVENUE SERVICE HAS DETERMINED THAT THE PROGRAM AND BTMF ARE TAX-EXEMPT ORGANIZATIONS UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. THE NOT-FOR-PROFIT STATUS OF THE PROGRAM AND BTMF ARE CONSIDERED TAX POSITIONS UNDER FASB ASC 740, INCOME TAXES. THE ORGANIZATION FOLLOWS THE ACCOUNTING STANDARDS FOR CONTINGENCIES IN EVALUATING UNCERTAIN TAX POSITIONS. THIS GUIDANCE PRESCRIBES RECOGNITION THRESHOLD PRINCIPLES FOR THE FINANCIAL STATEMENT RECOGNITION OF TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN ON A TAX RETURN THAT ARE NOT CERTAIN TO BE REALIZED. NO LIABILITY HAS BEEN RECOGNIZED BY THE ORGANIZATION FOR UNCERTAIN TAX POSITIONS AS OF SEPTEMBER 30, 2022 OR 2021. THE ORGANIZATION'S TAX RETURNS ARE SUBJECT TO REVIEW AND EXAMINATION BY FEDERAL AND STATE AUTHORITIES. PART XI, LINE 2D - OTHER ADJUSTMENTS: DIRECT FUNDRAISING EVENT AND GAMING EXPENSES 684,942. PART XII, LINE 2D - OTHER ADJUSTMENTS: DIRECT FUNDRAISING EVENT AND GAMING EXPENSES 684,942. 1 NORTH AMERICA 0 0 GRANTMAKING OTHER PROGRAM SERVICES - BONE MARROW/ STEM CELL DONOR ASSISTANCE 5745 0 0 0 0 0 0 5745 0 5745 BONE MARROW/ STEM CELL DONOR ASSISTANCE NORTH AMERICA 12 5745 0 0 1 0 0 0 PART I, LINE 2: THE GRANT PROVIDED TO NORTH AMERICA INCLUDES GRANTS TO BOTH MEXICO AND CANADA IS PART OF A BONE MARROW/STEM CELL DONOR ASSISTANCE PROGRAM THAT IS A LONG STANDING PROGRAM THAT PROVIDES ASSISTANCE WHEN AN EMPLOYER DOES NOT COVER WAGES WHEN A DONOR IS MAKING A DONATION. THE GRANTEES ARE REQUIRED TO SUBMIT AN EMPLOYER LETTER OR A PAY STUB TO DEMONSTRATE THE LOST WAGES. A BE THE MATCH (BTM) REPRESENTATIVE COMPLETES THE APPLICATION ON BEHALF OF THE DONOR. AN INTERNAL TEAM REVIEWS ALL APPLICATIONS AND SUPPORTING DOCUMENTS. PART III ACCOUNTING METHOD: X X X X X X 1 ALLEGIANCE FUNDRAISING GROUP PO 9132 FARGO ND 58104 FUNDRAISING CONSULTING 0 0 271044 -271044 THE STELTER COMPANY 10435 NEW YORK AVE DES MOINES IA 50322 GIFT & NEWSLETTER CONSULTANT 0 0 42658 -42658 MMS USA INVESTMENTS INC DBA EPSILON AGENCY LLC 35 WEST WACKER DRIVE CHICAGO IL 60601 FUNDRAISING CONSULTING 0 0 42200 -42200 GOODUNITED 769 MEETING STREET CHARLESTON SC 29403 FUNDRAISING CONSULTING 0 0 36617 -36617 MICHAEL TUBMAN 2750 ALAMO CIRCLE NE BLAINE MN 55449 FUNDRAISING CONSULTING 0 0 26250 -26250 418769 -418769 AL AK AR CA CO CT FL GA HI IL KS KY ME MD MA MI MN MO MS NV NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI THE BE THE MATCH GALA 1696638 1619649 76989 121208 75102 72509 84190 THE BE THE MATCH GALA NEW YORK 309714 284989 24725 3127 126822 53920 12971 2 274668 266394 8274 44357 45692 23809 15260 2281020 2171032 109988 3127 292387 120794 150238 112421 678967 -568979 26600 5330 645 0 26600 5330 645 5975 20625 MN 1 0 1 0 1.00000 JOY KING 500 N 5TH STREET MINNEAPOLIS MN 55401 0 STACEY CHASE GAMING COORDINATOR X 0 SCHEDULE G, PART I, LINE 2B, COLUMN (V) THE GROSS RECEIPTS FROM THE ACTIVITIES THAT PROFESSIONAL FUNDRAISERS ASSIST THE ORGANIZATION ON ARE NOT ABLE TO BE SEPARATELY REPORTED AS THE WORK AIDS IN MANY FUNDRAISING INITIATIVES THROUGHOUT THE FISCAL YEAR. SCHEDULE G, PART II, LINE 1: BE THE MATCH FOUNDATION'S FISCAL YEAR IS OCTOBER 1 - SEPTEMBER 30. THE ANNUAL GALA EVENT IS ROUTINELY HELD AT THE END OF SEPTEMBER: HOWEVER IN 2021, THE EVENT WAS HELD ON OCTOBER 1, 2021 WHICH WAS OUTSIDE OF THE 2020 FORM 990 REPORTING PERIOD. THE REVENUE AND EXPENSES INCURRED DURING FY2021 WERE CAPTURED IN THE 2020 FORM 990 AND ADDITIONAL REVENUE AND EXPENSES REPORTED HAVE BEEN REPORTED WITHIN THE NATIONAL GALA EVENT IN THE 2021 FORM 990. OTHER GAMING MANAGER INCLUDES AMANDA ALBERTSON WHO OBTAIN LISCENSES AND MANAGES THE PLANNING AND EXUCUTION OF RAFFLES. 1 NATIONAL MARROW DONOR PROGRAM 500 N 5TH STREET MINNEAPOLIS MN 55401 840865803 501(C)(3) 497167 0 VARIOUS NMDP PROGRAMS NATIONAL MARROW DONOR PROGRAM 500 N 5TH STREET MINNEAPOLIS MN 55401 840865803 501(C)(3) 1497649 0 BTMM PATIENT ASSISTANCE NATIONAL MARROW DONOR PROGRAM 500 N 5TH STREET MINNEAPOLIS MN 55401 840865803 501(C)(3) 74612 0 CLINICAL TRIALS SUPPORT NATIONAL MARROW DONOR PROGRAM 500 N 5TH STREET MINNEAPOLIS MN 55401 840865803 501(C)(3) 100000 0 DONOR RECRUITMENT NATIONAL MARROW DONOR PROGRAM 500 N 5TH STREET MINNEAPOLIS MN 55401 840865803 501(C)(3) 2720058 0 RESEARCH UNIVERSITY OF CALIFORNIA SAN FRANCISCO FOUNDATION 2001 THE EMBARCEDARO 3RD FLOOE SAN FRANCISCO CA 94133 942829914 501(C)(3) 35000 0 RESEARCH CHILDRENS HOSPITAL CORPORATION 300 LONGWOOD AVENUE BOSTON MA 02115 042774441 501(C)(3) 80000 0 RESEARCH/SCHOLAR FRED HUTCHINSON CANCER RESEARCH CENTER MAILSTOP LF-272 PO BOX 19024 SEATTLE WA 98109 237156071 501(C)(3) 276000 0 RESEARCH/SCHOLAR H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE 12902 MAGNOLIA DRIVE TAMPA FL 33612 593238634 501(C)(3) 36000 0 RESEARCH/SCHOLAR MEMORIAL SLOAN KETTERING CANCER CENTER 633 3RD AVENUE 4TH FLOOR NEW YORK NY 10017 131924236 501(C)(3) 80000 0 RESEARCH/SCHOLAR UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 1515 HOLCOMBE BOULEVARD HOUSTON TX 77030 746001118 501(C)(3) 80000 0 RESEARCH/SCHOLAR UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL PO BOX 402420 ATLANTA GA 30384 566001393 501(C)(3) 80000 0 RESEARCH/SCHOLAR UNIVERSITY OF ALABAMA 701 20TH STREET SOUTH BIRMINGHAM AL 35294 630649108 501(C)(3) 80000 0 RESEARCH/SCHOLAR UNIVERSITY OF PITTSBURGH PO BOX 371220 PITTSBURGH PA 15251 250965591 501(C)(3) 19060 0 RESEARCH/SCHOLAR WASHINGTON UNIVERSITY OF ST LOUIS 600 SOUTH EUCLID AVENUE ST LOUIS MO 63110 430654872 501(C)(3) 80000 0 RESEARCH/SCHOLAR NATIONAL MARROW DONOR PROGRAM 500 N 5TH STREET MINNEAPOLIS MN 55401 840865803 501(C)(3) 0 314847 BOOK SALARY PROGRAM SUPPORT 11 0 PATIENT TRANSPLANT ASSISTANCE 2019 3557475 CLINICAL TRIALS ASSISTANCE 98 353600 PATIENT TYPING & SEARCH ASSISTANCE 244 731896 DONOR ASSISTANCE 318 256955 PART I, LINE 2: PROCEDURE FOR MONITORING THE USE OF GRANT FUNDS INSIDE THE U.S. PATIENT ASSISTANCE GRANTS ARE AWARDED THROUGH BTMF. PATIENTS APPLY FOR PRE AND POST-TRANSPLANT SUPPORT GRANTS THROUGH THE ONLINE APPLICATION. THESE APPLICATIONS AND PATIENT ASSISTANCE ARE TRACKED IN THE ORACLE CUSTOM-BUILT MODULE AND MONITORED BY THE PATIENT OUTCOMES AND EXPERIENCES TEAM, A DEPARTMENT WITHIN NATIONAL MARROW DONOR PROGRAM (NMDP). THIS TEAM REVIEWS APPLICATIONS WEEKLY AND DETERMINES ASSISTANCE NEEDS BASED ON PUBLISHED CRITERIA, ALL WITH THE GOAL TO EQUITABLY ADMINISTER TO HELP PATIENTS OVERCOME BARRIERS BEFORE AND AFTER TRANSPLANT. SEARCH ASSISTANCE FUNDS ARE AWARDED TO COVER UNINSURED DONOR SEARCH COSTS. WHEN A TRANSPLANT CENTER (ORGANIZATIONS) RECEIVES AN INSURANCE DENIAL LETTER FOR DONOR SEARCH COSTS THEY ARE ABLE TO COMPLETE AN APPLICATION THAT INCLUDES PROVIDING A COPY OF THE DENIAL LETTER. IF APPROVED THE GRANT IS THEN DISTRIBUTED DIRECTLY TO THE TRANSPLANT CENTER. ALL OTHER PATIENT ASSISTANCE GRANTS ARE AWARDED TO THE APPLICANT BASED ON FINANCIAL NEED AND ARE USED TO COVER SUCH ITEMS AS UNINSURED COSTS, CO-PAYS, FOOD, LODGING, AND GROUND TRANSPORTATION. PAYMENTS ARE MADE DIRECTLY TO THE PATIENT/APPLICANT (INDIVIDUAL). DONOR ASSISTANCE CHECKS ARE ALSO AWARDED TO THE APPLICANT BASED ON FINANCIAL NEEDS AND ARE USED TO OFFSET HAVING TO TAKE UNPAID TIME OFF FROM WORK IN ORDER TO DONATE LIFE-SAVING CELLS. PAYMENTS ARE MADE DIRECTLY TO THE DONOR (INDIVIDUAL). 0 1 0 0 0 0 0 0 0 AMY RONNEBERG CHIEF EXECUTIVE OFFICER 0 700962 0 457400 0 21855 0 25496 0 23 0 1205736 0 0 JOY KING EXEC. DIR. BTMF/SVP PHILAN. 113398 170098 55430 83144 3979 5968 10198 15298 9143 13715 192148 288223 0 0 GINA GRAVES FORMER OFFICER 0 211353 0 85255 0 9392 0 25496 0 10193 0 341689 0 0 KRISTA DUSIL CHIEF FINANCIAL OFFICER 0 201301 0 104895 0 6050 0 0 0 18105 0 330351 0 0 TODD A PETERSON VICE PRESIDENT 162585 0 43911 0 1149 0 15340 0 25560 0 248545 0 0 0 ANGIE FITZGERALD SENIOR DIR., CORPORATE PARTNERSHIPS 132405 0 28736 0 982 0 9691 0 24813 0 196627 0 0 0 DANIEL LEE DIRECTOR, MAJOR AND PLANNED GIFTS 133182 0 27514 0 859 0 9034 0 16260 0 186849 0 0 0 JACQUELINE CHANDONNET DIRECTOR, DEVELOPMENT 145011 0 14150 0 1274 0 10840 0 9639 0 180914 0 0 0 KRISTIN SCOTT MANAGER, MAJOR GIFTS 129426 0 19231 0 877 0 8146 0 5714 0 163394 0 0 0 JEFFREY CHELL FORMER OFFICER 0 0 0 0 0 101795 0 0 0 0 0 101795 0 0 PART I, LINE 3 TOP MANAGEMENT'S COMPENSATION: BTMF USES NMDP'S COMPENSATION COMMITTEE WHICH IS CHARGED WITH SETTING THE COMPENSATION OF NMDP'S CEO.AS REPORTED ON NMDP'S FORM 990, SCHEDULE J, A COMPENSATION COMMITTEE, INDEPENDENT COMPENSATION CONSULTANT, WRITTEN EMPLOYMENT CONTRACT, COMPENSATION SURVEY OR STUDY, AND APPROVAL BY THE BOARD OR COMPENSATION COMMITTEE ARE ALL UTILIZED WHEN DETERMINING COMPENSATION. PLEASE ALSO SEE THE SCHEDULE O, FORM 990, PART VI, SECTION B, LINE 15 NARRATIVE. PART I, LINE 4B THE ORGANIZATION OFFERS A SUPPLEMENTAL BENEFITS PLAN (THE SUPPLEMENTAL PLAN) FOR ITS OFFICERS, SENIOR VICE PRESIDENTS AND VICE PRESIDENTS. ALL SUPPLEMENTAL PLAN PARTICIPANTS RECEIVED $750,000 IN LIFE INSURANCE, LONG-TERM DISABILITY AND LONG-TERM CARE INSURANCE. PREMIUMS ARE PAID BY THE ORGANIZATION AND ARE TREATED AS TAXABLE INCOME TO PLAN PARTICIPANTS. FUTURE BENEFITS RECEIVED UNDER THE PLAN, IF ANY, WILL NOT BE TAXED. THE SUPPLEMENTAL PLAN WAS CREATED IN ACCORDANCE WITH APPLICABLE PROVISIONS OF THE INTERNAL REVENUE CODE (IRC SEC 7702). X 8 112860 FMV X AUCTION ITEMS 210 155415 FMV X ADVERTISEMENT 1 2375 FMV X GIFT CARDS 15 2250 FMV 0 0 1 0 PART I, COLUMN (B): METHOD USED BTMF USES THE NUMBER OF CONTRIBUTIONS AS THE METHOD FOR DETERMINING THE AMOUNT IN COLUMN (B). FORM 990, PART I, LINE 1, DESCRIPTION OF ORGANIZATION MISSION: BE THE MATCH IS A GLOBAL LEADER WORKING EVERY DAY TO SAVE LIVES THROUGH CELLULAR THERAPY. FOR PEOPLE WITH LIFE-THREATENING BLOOD CANCERS-LIKE LEUKEMIA AND LYMPHOMA-OR OTHER BLOOD DISORDERS LIKE SICKLE CELL, A CURE EXISTS. BE THE MATCH CONNECTS PATIENTS WITH A MATCHING DONOR FOR A LIFE-SAVING BLOOD STEM CELL TRANSPLANT. THE BE THE MATCH REGISTRY IS THE MOST DIVERSE REGISTRY IN THE WORLD AND INCLUDES BOTH ADULT DONORS WILLING TO DONATE TO A STRANGER IN NEED AND STORED CORD BLOOD UNITS. IN ADDITION, BE THE MATCH PROVIDES PATIENTS AND THEIR FAMILIES ONE-ON-ONE SUPPORT, EDUCATION, AND GUIDANCE BEFORE, DURING AND AFTER TRANSPLANT. BE THE MATCH IS ALSO A GLOBAL LEADER IN RESEARCH THROUGH THE CIBMTR (CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH), A COLLABORATION WITH MEDICAL COLLEGE OF WISCONSIN, INVESTING IN AND MANAGING RESEARCH STUDIES THAT IMPROVE PATIENT OUTCOMES AND ADVANCE THE FUTURE OF CARE. THE BE THE MATCH FOUNDATION RAISES FUNDS TO HELP PATIENTS BY: - ADDING NEW POTENTIAL DONORS TO THE REGISTRY - HELPING PAY UNINSURED PATIENT COSTS ASSOCIATED WITH TRANSPLANT - FUNDING LIFE-SAVING RESEARCH THROUGH THE CIBMTR AS THE WORLD'S LEADING NONPROFIT ORGANIZATION FOCUSED ON SAVING LIVES THROUGH CELLULAR THERAPY, BE THE MATCH CONTINUES TO IMPROVE ACCESS TO TRANSPLANT BY LEADING EFFORTS TO REMOVE BARRIERS TO TREATMENT AND STRENGTHEN OUR ABILITY TO MEET THE GROWING NEED.THROUGH OUR GLOBAL NETWORK, WE CONNECT CENTERS AND PATIENTS TO BEST CELL THERAPY OPTIONS FROM BLOOD STEM CELL TRANSPLANT TO A NEXT-GENERATION THERAPY AND COLLABORATE WITH CELL AND GENE THERAPY COMPANIES TO SUPPORT THERAPY DEVELOPMENT AND DELIVERY THROUGH BE THE MATCH BIOTHERAPIES. THE DEFINITION FOR THE BE THE MATCH TRUE NORTH GOAL OF LIVES EQUALS THE NUMBER OF PATIENTS WHO RECEIVE BE THE MATCH-FACILITATED CELL THERAPIES. AS THE USE OF THERAPIES EXPANDS, SO HAS BE THE MATCH'S WORK IN UNRELATED AND RELATED DONOR TRANSPLANTS AND BIOTHERAPIES AUTOLOGOUS (DONATION FOR SELF), ALLOGENEIC (DONATION FOR NON-SPECIFIC PATIENT) AND CLINICAL TRIALS. THE VISION OF BE THE MATCH IS FOR EVERY PATIENT TO RECEIVE A TRANSPLANT NO MATTER THEIR ETHNIC BACKGROUND. EVERY YEAR, MORE PATIENTS ARE RECEIVING THE LIFE-SAVING MARROW OR CORD BLOOD TRANSPLANT THEY NEED BECAUSE OF THE COMMUNITY OF DONORS, VOLUNTEERS, HEALTH CARE PROFESSIONALS, RESEARCHERS AND FINANCIAL SUPPORTERS. FORM 990, PART I, LINE 12: TOTAL REVENUE DECREASED FROM PRIOR YEAR PRIMARILY DRIVEN BY CONTRIBUTIONS FROM RELATED ORGANIZATIONS (FORM 990, PART VIII, STATEMENT OF REVENUE, SECTION I, LINE D). NATIONAL MARROW DONOR PROGRAM (NMDP) PROVIDED $7.7M IN 2020 VS. $1.6M IN 2021. BE THE MATCH FOUNDATION (BTMF) IS OPERATED BY NMDP AND REGULARLY RECORDS INTERCOMPANY ACTIVITY. IN 2020 INTERCOMPANY REVENUE OF $7.7M WAS RECORDED TO BTMF TO REFLECT THE FORGIVENESS OF INTERCOMPANY BALANCES. IN 2021, BTMF SETTLED THE INTERCOMPANY PAYABLE RESULTING IN NO NEEDED FORGIVENESS OF OUTSTANDING INTERCOMPANY BALANCES. IN 2021 INTERCOMPANY REVENUE OF $1.6M REPRESENTS PATIENT FINANCIAL ASSISTANCE GRANT FUNDING PROVIDED FROM NMDP. FORM 990, PART VI, SECTION A, LINE 2 THE FOLLOWING DIRECTORS OF BTMF HAVE A REPORTABLE BUSINESS RELATIONSHIP: ANNE MCGEORGE AND AMY RONNEBERG (MS. MCGEORGE AND MS. RONNEBERG WERE BOTH VOTING DIRECTORS OF MAGENTA THERAPEUTICS DURING FY2022). FORM 990, PART VI, SECTION A, LINE 6 MEMBERS OR STOCKHOLDERS: NMDP IS THE SOLE CORPORATE MEMBER OF BTMF. FORM 990, PART VI, SECTION A, LINE 7A MEMBERS OR STOCKHOLDERS WHO MAY ELECT GOVERNING BODY: THE NMDP BOARD ELECTS THE BOARD OF DIRECTORS OF BTMF. FORM 990, PART VI, SECTION A, LINE 7B MEMBERS OR STOCKHOLDERS WHO MAY APPROVE DECISIONS: THE NMDP BOARD APPROVES THE ACTIONS OF BTMF. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 REVIEW PROCESS: THE ORGANIZATION CONTRACTED WITH THE OUTSIDE PUBLIC ACCOUNTING FIRM, BAKER TILLY, TO PREPARE THE FORM 990. PREPARING THE DETAILS AND SUPPORTING REPORTS FOR THE RETURN IS A COLLABORATIVE EFFORT AMONG A SMALL GROUP OF INDIVIDUALS IN THE FINANCIAL REPORTING & COMPLIANCE AREA OF FINANCE, INTERNAL AUDIT AND HUMAN RESOURCES. THAT WORK IS THEN REVIEWED BY THE SENIOR MANAGER OF FINANCIAL REPORTING PRIOR TO SENDING TO BAKER TILLY; THE CHIEF LEGAL OFFICER ALSO REVIEWS THE GOVERNANCE SECTIONS PRIOR TO SENDING TO BAKER TILLY. ONCE A DRAFT IS RECEIVED BACK FROM BAKER TILLY, IT IS REVIEWED BY THE TEAM THAT PULLED THE DETAILS TOGETHER, NMDP ACTING CHIEF FINANCIAL OFFICER AND EXECUTIVE DIRECTOR OF BTMF. A COPY OF THE RETURN IS PROVIDED TO THE NMDP AUDIT AND FINANCE COMMITTEE AND BTMF BOARD OF DIRECTORS PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY STATES THE FOLLOWING: "THE EXISTENCE OF AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST TURNS ON THE SPECIFIC FACTS AND CIRCUMSTANCES IN EACH CASE. IF A MEMBER HAS AN INTEREST WHICH MAY CONFLICT WITH THOSE OF THE ORGANIZATIONS, HE OR SHE MUST IMMEDIATELY DISCLOSE THE MATTERS AND DISCUSS THEM FULLY AND FRANKLY WITH THE APPLICABLE ORGANIZATION'S FULL BOARD OR ITS EXECUTIVE COMMITTEE, AS SET FORTH IN DETAIL BELOW. A MEMBER MUST NOT PARTICIPATE IN ANY MATTER IN WHICH THAT MEMBER MAY HAVE AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST WITHOUT THE EXPRESS APPROVAL OF THE APPLICABLE ORGANIZATION'S BOARD OF DIRECTORS OR EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS (EXECUTIVE COMMITTEE). ALL MEMBERS MUST DISCLOSE TO THE APPLICABLE ORGANIZATION'S BOARD OF DIRECTORS OR EXECUTIVE COMMITTEE ALL CONFLICTS OF INTEREST AND REPORTABLE RELATIONSHIPS, AND MUST ANNUALLY COMPLETE AND SUBMIT THE CONFLICT OF INTEREST QUESTIONNAIRE WHICH IS REQUIRED BY THIS POLICY. WHENEVER IN THE COURSE OF EVENTS A MEMBER'S CIRCUMSTANCES CHANGE SUCH THAT THE MEMBER KNOWS OR HAS REASON TO BELIEVE THAT THE MEMBER MAY HAVE AN ACTUAL OR PERCEIVED CONFLICT OF INTEREST, SUCH MEMBER SHALL PROMPTLY DISCLOSE THE POTENTIAL CONFLICT TO THE APPLICABLE ORGANIZATION'S BOARD OF DIRECTORS OR EXECUTIVE COMMITTEE. FOR THE PURPOSES OF THIS ARTICLE, A MEMBER MAY FORMALLY DISCLOSE A CONFLICT OR REPORTABLE RELATIONSHIP TO THE CHIEF EXECUTIVE OFFICER (CEO) OF NMDP, THE CHIEF ADVANCEMENT OFFICER/BTMF EXECUTIVE DIRECTOR, OR THE NMDP CHIEF LEGAL OFFICER AND POLICY OFFICER/GENERAL COUNSEL (CLO), AS APPLICABLE, WHO SHALL INFORM THE APPLICABLE ORGANIZATION'S BOARD OF DIRECTORS OR EXECUTIVE COMMITTEE FOR RESOLUTION. AS NOTED HEREIN, IF THE POTENTIAL CONFLICT INVOLVES A DIRECTOR OR COMMITTEE MEMBER, THAT DIRECTOR OR COMMITTEE MEMBER SHALL NOT PARTICIPATE IN OR VOTE UPON SUCH MATTERS UNTIL THE QUESTION OF THE EXISTENCE OF THE CONFLICT OF INTEREST HAS BEEN RESOLVED IN ACCORDANCE WITH THIS POLICY. LIKEWISE, AN OFFICER OR KEY EMPLOYEE MAY NOT BECOME SUBSTANTIALLY INVOLVED IN DECISION-MAKING INVOLVING ANY COVERED LITIGATION, CONTRACT OR TRANSACTION UNTIL THE RESOLUTION OF THE MATTER IN ACCORDANCE WITH THIS POLICY." FORM 990, PART VI, SECTION B, LINE 15 PROCESS FOR DETERMINING COMPENSATION: THE BTMF CHIEF ADVANCEMENT OFFICER REPORTS DIRECTLY TO THE NMDP CEO AND IS CONSIDERED A KEY EMPLOYEE PER THE IRS DEFINITION. THE COMPENSATION OF THE BTMF CHIEF ADVANCEMENT OFFICER IS REVIEWED, EVALUATED, AND SET IN ACCORDANCE WITH THE NMDP BYLAWS AND COMPENSATION COMMITTEE CHARTER. THE NMDP BYLAWS STATE: "THE COMPENSATION COMMITTEE SHALL BE COMPRISED ONLY OF VOTING DIRECTORS AND SHALL INCLUDE THE CHAIR OF THE BOARD AND AT LEAST ONE (1) NON-OFFICER BOARD MEMBER AS VOTING COMMITTEE MEMBERS. THE COMPENSATION COMMITTEE SHALL REVIEW AND EVALUATE THE OVERALL COMPENSATION AND BENEFIT STRUCTURE OF THE CORPORATION AND SHALL HAVE SUCH OTHER AUTHORITY AND RESPONSIBILITIES AS SET FORTH IN THE COMPENSATION COMMITTEE CHARTER." THE COMPENSATION COMMITTEE CHARTER STATES: "THE COMMITTEE SHALL REVIEW AND EVALUATE THE OVERALL COMPENSATION AND BENEFIT STRUCTURE OF THE CORPORATION, AND APPROVE AND ADOPT A COMPENSATION PHILOSOPHY AND PRINCIPLES CONSISTENT WITH THE CORPORATION'S NOT-FOR-PROFIT STATUS (THE COMPENSATION PHILOSOPHY AND PRINCIPLES). THE COMMITTEE SHALL CONDUCT THE CHIEF EXECUTIVE OFFICER (CEO) PERFORMANCE EVALUATION. THE COMMITTEE SHALL MAKE CEO TOTAL COMPENSATION AND BENEFIT RECOMMENDATIONS TO THE EXECUTIVE COMMITTEE, CONSISTENT WITH THE COMPENSATION PHILOSOPHY AND PRINCIPLES. IN MAKING COMPENSATION AND BENEFIT RECOMMENDATIONS FOR THE CEO, THE COMMITTEE SHALL UTILIZE, AMONG OTHER THINGS, COMPARABILITY DATA FOR COMPLIANCE WITH IRS INTERMEDIATE SANCTION PROVISIONS SO AS TO ALLOW THE CORPORATION TO TAKE ADVANTAGE OF THE REBUTTABLE PRESUMPTION OF REASONABLENESS. ON A PERIODIC BASIS, THE COMMITTEE SHALL OBTAIN COMPARABILITY DATA FROM AN INDEPENDENT COMPENSATION CONSULTANT. IN ADDITION, THE COMMITTEE SHALL ADVISE THE CEO IN HIS/HER/THEIR EVALUATION OF AND DECISIONS REGARDING THE COMPENSATION OF AND BENEFITS FOR SENIOR CORPORATION EMPLOYEES, AS WELL AS THE PRESIDENT (OR EQUIVALENT LEADER) OF ANY SUBSIDIARY OF THE CORPORATION REPORTING TO THE CEO (TOGETHER, SENIOR LEADERSHIP). IN ADVISING THE CEO IN MAKING HIS/HER/THEIR COMPENSATION AND BENEFIT DECISIONS FOR SENIOR LEADERSHIP, THE COMMITTEE SHALL ENSURE THAT SUCH DECISIONS ARE CONSISTENT WITH THE COMPENSATION PHILOSOPHY AND PRINCIPLES, AND UTILIZE, AMONG OTHER THINGS, COMPARABILITY DATA FOR COMPLIANCE WITH IRS INTERMEDIATE SANCTION PROVISIONS. IF DECISIONS PROPOSED BY THE CEO ARE OUTSIDE THE PARAMETERS OF THE COMPENSATION PHILOSOPHY AND PRINCIPLES, THE CEO MUST OBTAIN THE COMMITTEE'S APPROVAL PRIOR TO IMPLEMENTATION." FORM 990, PART VI, SECTION C, LINE 19 HOW DOCUMENTS ARE MADE AVAILABLE TO THE PUBLIC: THE CONFLICT OF INTEREST POLICY, ARTICLES OF INCORPORATION AND CONSOLIDATED AUDITED FINANCIAL STATEMENTS AND ADDITIONAL CONSOLIDATING INFORMATION ARE ALL MADE AVAILABLE TO THE PUBLIC UPON REQUEST. THE CONSOLIDATED AUDITED FINANCIAL STATEMENTS ARE ALSO AVAILABLE ON OUR WEBSITE. SUMMARY FINANCIAL STATEMENTS ARE ALSO INCLUDED IN OUR ANNUAL REPORT, WHICH IS MAILED TO KEY STAKEHOLDERS AND POSTED ON OUR WEBSITE. ADDITIONALLY, ARTICLES OF INCORPORATION ARE AVAILABLE AT THE MN OFFICE OF THE SECRETARY OF STATE, AND CONSOLIDATED AUDITED FINANCIAL STATEMENTS MAY BE OBTAINED AT THE MN OFFICE OF THE ATTORNEY GENERAL. FORM 990, PART XII, LINE 2C: THE ORGANIZATION HAS NEITHER CHANGED ITS OVERSIGHT PROCESS OR SELECTION PROCESS DURING THE TAX YEAR. NATIONAL MARROW DONOR PROGRAM 500 N 5TH STREET MINNEAPOLIS MN 554011206 840865803 TRANSPLANTS CO 501(C)(3) LINE 10 N/A 0 BE THE MATCH MX AC VERACRUZ AV 93 101 PISO CUIDAD DE MEXICO CONDESA MX RECRUITMENT MX NMDP 0 BE THE MATCH AUXILIARY SERVICES LLC 500 N 5TH ST MINNEAPOLIS MN 554011206 811248190 CELLULAR THERAPY MN N/A C 0 CLEAR INSURANCE LTD 62 FORUM LN 3RD FL PO BOX 30600 GRAND CAYMAN CJ KY1-1203 840865803 CAPTIVE INSURANCE CJ N/A C 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0